Daily Stock Analysis, AKTX, Akari Therapeutics PLC, priceseries

Akari Therapeutics PLC. Daily Stock Analysis
Stock Information
Open
1.37
Close
1.29
High
1.37
Low
1.23
Previous Close
1.35
Daily Price Gain
-0.06
YTD High
1.54
YTD High Date
Jan 3, 2022
YTD Low
1.21
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.22
YTD Gain
-14.57%
52 Week High
3.32
52 Week High Date
Mar 17, 2021
52 Week Low
1.21
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.35
52 Week Gain
-51.14%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2017
7.80
Jan 20. 2017
8.30
3 Trading Days
6.41%
Link
LONG
Mar 29. 2017
6.65
Apr 17. 2017
13.96
12 Trading Days
109.98%
Link
LONG
Apr 20. 2017
16.37
Apr 25. 2017
17.29
3 Trading Days
5.59%
Link
LONG
Sep 8. 2017
4.00
Sep 28. 2017
6.66
14 Trading Days
66.52%
Link
LONG
Mar 13. 2019
5.90
Mar 14. 2019
7.55
1 Trading Days
27.97%
Link
LONG
Mar 18. 2019
4.57
Mar 19. 2019
5.04
1 Trading Days
10.18%
Link
LONG
Apr 22. 2019
3.35
Apr 26. 2019
3.60
4 Trading Days
7.36%
Link
LONG
May 29. 2020
2.04
Jun 10. 2020
2.22
8 Trading Days
8.93%
Link
LONG
Jul 1. 2020
2.37
Jul 2. 2020
2.52
1 Trading Days
6.12%
Link
LONG
Dec 2. 2020
1.63
Dec 21. 2020
1.84
13 Trading Days
12.77%
Link
LONG
Jan 7. 2021
1.95
Jan 28. 2021
2.78
14 Trading Days
42.58%
Link
LONG
Feb 12. 2021
2.81
Feb 23. 2021
3.11
6 Trading Days
10.72%
Link
Company Information
Stock Symbol
AKTX
Exchange
NasdaqGS
Company URL
http://www.akaritx.com
Company Phone
(646) 350-0702
CEO
Gur A. Roshwalb
Headquarters
New York
Business Address
24 WEST 40TH STREET, 8TH FLOOR, NEW YORK, NY 10018
Sector
-
Industry Category
-
Industry Group
-
CIK
0001541157
About

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded in 2005 and is headquartered in London, the United Kingdom.

Description

As of September 18, 2015, Celsus Therapeutics Plc was acquired by Akari Therapeutics, Plc, in a reverse merger transaction. Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-ste...